To achieve the highest possible variant detection for MEN1, labs must pair full-gene sequencing with a dedicated copy-number analysis method—typically MLPA.
Sequencing the entire coding region (all 10 exons) identifies a disease-causing variant in 80–90% of familial cases, but a meaningful fraction of patients remain unresolved. The missing piece is structural variation. Integrating copy-number variant (CNV) detection for large deletions and duplications adds an additional 1–4% yield, pushing the overall sensitivity to roughly 95% in familial MEN1. This combined strategy is the gold standard for diagnostic-grade testing.
The essence of maximum detection is sequencing every exon plus screening for gross structural changes. Sequencing alone misses big rearrangements; MLPA alone misses point mutations. Only by layering both will a lab confidently approach the theoretical detection ceiling in MEN1.
Why Sequencing Alone Falls Short of Maximum Sensitivity
The MEN1 Gene Has No Mutational Hotspots
Disease-causing variants are scattered across all 10 coding exons without a clear clustering pattern. There is no hotspot where you can focus and capture the majority of mutations. Full coverage of the coding region is mandatory.
Sequencing Captures Most – But Not All – Variants
Targeted sequencing of the entire MEN1 coding sequence—whether by Sanger or next-generation sequencing (NGS)—detects point mutations, small indels, and splice-site variants. In familial MEN1, this yields a pathogenic variant in 80–90% of cases. In seemingly sporadic presentations (no family history), the rate drops to about 65%. That still leaves a diagnostic gap.
The Gap Is Structural
The residual cases often harbor large deletions or duplications that are invisible to standard sequencing chemistries. These structural changes remove entire exons or large segments in cis, yet the raw sequencing reads may appear normal because the remaining allele is amplified. Without a dedicated structural assay, these variants go undetected.
The Sequencing Backbone: Sanger or NGS?
Full Coding Region Analysis Is Non-Negotiable
Regardless of the platform, the entire coding sequence plus flanking splice regions must be interrogated. Selective exon testing is insufficient. Any diagnostic workflow must start here.
NGS Offers Throughput and Flexibility
Most clinical labs now prefer a targeted NGS panel that includes MEN1 as part of a broader endocrine tumor gene set. NGS can reliably detect single-nucleotide variants and small indels across all exons in a single run. For MEN1-only testing, a high-quality custom panel or a whole-exome approach works, provided coverage is deep and uniform.
Sanger Remains a Valuable Confirmatory Tool
For labs without NGS infrastructure, bidirectional Sanger sequencing of all coding exons remains a highly accurate and validated approach. It is slower and more labor-intensive but can serve as the primary method or as orthogonal confirmation for NGS findings.
The Critical Complement: Copy-Number Variant Detection
Why CNVs Matter in MEN1
Large germline deletions (and, less commonly, duplications) account for an estimated 1–4% of MEN1 mutations in series that have already been screened negative by sequencing. This is a small but essential fraction—without CNV analysis, those patients would receive a false-negative result.
MLPA: The Workhorse for MEN1 CNV Detection
Multiplex Ligation-dependent Probe Amplification (MLPA) is the most widely used method for detecting exon-level copy-number changes. A MEN1-specific probe mix covers each exon, and relative peak-height analysis reveals deletions or duplications. It is cost-effective, accessible, and well-validated in the literature.
Alternative CNV Methods
- Array CGH or SNP arrays: Can detect larger deletions but may have lower resolution for single-exon events.
- NGS-based CNV calling algorithms: Emerging tools permit concurrent detection of structural variants from the same NGS data, reducing the need for a separate wet-lab step. However, validation against MLPA is still recommended before deploying this as a primary screen.
Building the Workflow for Maximum Yield
A Tiered Strategy Reduces Costs Without Sacrificing Sensitivity
A tiered approach is practical: sequence first, reflex to CNV only when sequencing is negative. This captures the high-yield sequence variants in the majority of patients and reserves MLPA for the subset where it is most informative. In familial cases, this combination reaches ~95% overall sensitivity.
Simultaneous Testing Is Faster but More Expensive
For labs prioritizing turnaround time—such as those supporting acute clinical decision-making or newborn screening follow-up—running sequencing and MLPA in parallel on every sample eliminates the need for a second round. The incremental cost of MLPA is modest, and concurrent testing guarantees the highest single-pass detection rate.
Integration into Broader Endocrine Tumor Panels
If MEN1 is part of a multi-gene NGS panel, ensure the informatics pipeline includes robust CNV calling across the MEN1 locus. This unifies variant detection in one workflow. If the panel’s CNV performance is unproven, a backup MLPA confirmation is prudent for any structural call or for sequencing-negative samples.
Understanding the Trade-offs
MLPA Adds Sensitivity but Introduces Interpretation Nuances
MLPA is highly sensitive for whole-exon and multi-exon deletions or duplications. However, it will miss variants located at the probe-binding site if they disrupt probe hybridization, potentially mimicking a deletion. Orthogonal confirmation (e.g., long-range PCR, qPCR) may be needed for ambiguous results.
NGS CNV Calling Is Convenient but Immature
Leveraging NGS data for CNV detection reduces laboratory work but requires stringent coverage uniformity and complex algorithmic normalization. False positives due to GC bias or batch effects are common, and false negatives can occur for single-exon events. Labs using NGS-only CNV methods should maintain a low threshold for reflexing to MLPA.
Cost, Throughput, and Regulatory Context
Adding a second test adds per-sample cost and may extend turnaround. Labs operating under CLIA or equivalent regulations must validate any combined strategy as a complete assay, including CNV components. The cost-benefit equation tilts strongly in favor of CNV addition when the clinical consequence of a missed diagnosis is high—as in MEN1, where early tumor surveillance and prophylactic interventions directly affect patient outcomes.
Making the Right Choice for Your Lab’s Goals
The optimal complementary strategy depends on your workflow priorities and patient population.
- If your primary focus is maximum sensitivity in a high-clinical-acuity setting: Run full-gene sequencing and MLPA simultaneously on every sample. Accept the incremental cost for a near-95% detection rate in a single pass.
- If your primary focus is cost-effective, high-throughput familial screening: Use a tiered approach: sequence all coding exons first, then reflex to MLPA only for sequence-negative cases. You will still achieve the same combined sensitivity while minimizing the number of MLPA reactions.
- If your primary focus is seamless integration with a multi-gene NGS panel: Invest in validating CNV calling from NGS data against MLPA. Use the NGS CNV algorithm as the primary screen, but retain MLPA as a confirmation tool for any uncertain or single-exon calls and for all sequence-negative samples.
- If your primary focus is sporadic MEN1 cases: Recognize that detection rates start at ~65% with sequencing alone. The addition of CNV analysis may add 1–4%, but a negative combined result still leaves a residual risk and may warrant exploration of phenocopy genes or somatic mosaicism.
Pairing exhaustive coding-region sequencing with targeted structural variant analysis—most practically via MLPA—is the single most effective way to push MEN1 variant detection to its maximum achievable limit without over-engineering the workflow.
Summary Table:
| Strategy | Variant Spectrum Covered | Familial Yield | Primary Role & Best Use Case |
|---|---|---|---|
| Full-Gene Sequencing (NGS / Sanger) | SNVs, small indels, splice-site variants | 80–90% | Primary screen for all 10 coding exons; catches point mutations. |
| CNV Analysis (MLPA / Array) | Exon-level & large structural deletions/duplications | +1–4% | Essential reflex screen; identifies gross structural changes missed by sequencing. |
| Combined Workflow (Sequencing + MLPA) | Complete spectrum (SNVs, indels, and large CNVs) | ~95% | Gold Standard: Tiered or parallel approach to achieve maximum clinical sensitivity. |
Developing or optimizing diagnostic-grade molecular panels for MEN1 and endocrine tumors? CamelBio provides diagnostic manufacturers, clinical labs, and research institutes with one-stop access to premium IVD raw materials, specialized technical services, and expert regulatory consulting—supporting every stage from concept to clinic.
Contact CamelBio today to enhance your molecular assay sensitivity and streamline your workflow!